InsiderTrades.com logo

Konstantinos Xynos Biography and Net Worth

Chief Medical Officer of Replimune Group
  • LinkedIn
  • Phone
  • Email
  • Website


Kostas Xynos, MD, PhD, MBA, Joined Replimune in December 2021 bringing over 15 years of global biopharmaceutical experience in hematology and oncology drug development and medical affairs. Dr. Xynos joined Replimune from Deciphera where he spent the last three years, as Vice President of Global Medical Affairs. Prior to Deciphera, he spent nine years at AbbVie and three years at Astellas in increasingly senior global roles in oncology and hematology development as well as medical affairs. Dr. Xynos after receiving his BS in Biology at the University of Illinois, earned his MD at Aristoteleion University of Thessaloniki and his MBA at Strathclyde University in Scotland. He completed his internal medicine residency and fellowship at the University of Athens Alexandra hospital where he served as a researcher and has practiced clinical medicine for several years.

What is Konstantinos Xynos' net worth?

The estimated net worth of Konstantinos Xynos is at least $863,696.10 as of November 18th, 2024. Dr. Xynos owns 109,885 shares of Replimune Group stock worth more than $863,696 as of May 13th. This net worth estimate does not reflect any other assets that Dr. Xynos may own. Learn More about Konstantinos Xynos' net worth.

How old is Konstantinos Xynos?

Dr. Xynos is currently 58 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Konstantinos Xynos' age.

How do I contact Konstantinos Xynos?

The corporate mailing address for Dr. Xynos and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Konstantinos Xynos' contact information.

Has Konstantinos Xynos been buying or selling shares of Replimune Group?

Konstantinos Xynos has not been actively trading shares of Replimune Group within the last three months. Most recently, Konstantinos Xynos sold 7,246 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a transaction totalling $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company's stock, valued at $1,184,560.30. Learn More on Konstantinos Xynos' trading history.

Who are Replimune Group's active insiders?

Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.

Are insiders buying or selling shares of Replimune Group?

During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.

Information on this page was last updated on 12/16/2024.

Konstantinos Xynos Insider Trading History at Replimune Group

See Full Table

Konstantinos Xynos Buying and Selling Activity at Replimune Group

This chart shows Konstantinos Xynos's buying and selling at Replimune Group by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

Replimune Group Company Overview

Replimune Group logo
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Read More

Today's Range

Now: $7.86
Low: $7.67
High: $8.28

50 Day Range

MA: $9.27
Low: $6.92
High: $12.11

2 Week Range

Now: $7.86
Low: $4.92
High: $17.00

Volume

764,794 shs

Average Volume

895,234 shs

Market Capitalization

$605.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68